- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04624464
Assessing the Impact of Antimicrobial Exposure and Infection Control Measures on the Spread of VRE (AEGON)
Assessing the Impact of Antimicrobial Exposure and Infection Control Measures on the Spread of Vancomycin-resistant Enterococcus Faecium (VREf) - A Prospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current studies show that Vancomycin-resistant Enterococci (VRE) have become increasingly widespread throughout Germany in recent years, especially E. faecium (VREf). Healthy individuals can come into contact with VREf in various ways, for example via the food chain, contaminated drinking water or animal contacts. A possibly caused low-grade colonisation of the gastrointestinal tract with VREf (so-called low-level colonisation) can remain undetected during hospital admission using routine screening methods. The AEGON study, based on the use of state-of-the-art molecular diagnostics and comprehensive clinical data collection, will provide a detailed analysis of the factors involved in the rapid spread of VREf. In addition, diagnostic detection limits of common screening methods are determined by the use of additional diagnostics such as enrichment culture or molecular VREf detection.
The study is a German multicenter, prospective observational study and consists of two parts, which are carried out at all participating study sites and include two different patient cohorts. Part 1 focuses on the collection and analysis of rectal swabs from newly admitted VRE-negative patients at high risk of nosocomial VREf acquisition. Moreover, patients included into this part of the study will undergo in-depth documentation of clinical data if an antibiotic therapy is administered. Initiated antibiotic therapies will then be assessed by an AMS board. In Part 2, environmental investigations will be performed in newly occupied single rooms of previously known VREf-positive patients. In addition, rectal swabs will be collected and data on antibiotic exposure of these patients will be documented in order to correlate the VRE contamination burden of surfaces with the intestinal VREf-load and antibiotic exposure. The AEGON study, based on the use of state-of-the-art molecular diagnostics and comprehensive clinical data collection, will provide a detailed analysis of the factors involved in the rapid spread of VREf. In addition, diagnostic detection limits of common screening methods are determined by the use of additional diagnostics such as enrichment culture or molecular VREf detection.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
NRW
-
Cologne, NRW, Germany, 50931
- Recruiting
- University Hospital of Cologne
-
Contact:
- Jörg Janne Vehreschild, MD
- Email: joerg.vehreschild@uk-koeln.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The selection of patients to be included in Part 1 of the AEGON study is based on the risk stratification for the nosocomial acquisition of VREf performed in the CONTROL study.
It is planned to include a total of 150 patients from the participating study centers in Part 1. Based on the results of the CONTROL study, it can be assumed that within the selected target group in approx. 11% there is already an VREf colonisation by direct culture at admission and in 15% of the cases (22 of 150 patients) a nosocomial acquisition of VREf by direct culture (see method part) can be determined. Patients with VREcolonization detected at admission are excluded from the study.
Description
Part 1
Inclusion Criteria:
- ≥ 18 years
- Patients with malignant primary disease and current inpatient admission to a normal ward with expected inpatient stay of at least 15 days
- High risk of exposure to antibiotics during the stay
- Written informed consent of the patient after clarification has been given
Exclusion Criteria:
- Already known current or documented past colonisation or infection by VRE
- Simultaneous participation in other studies is only an exclusion criterion if the other study explicitly excludes participation in observational studies or if the other study complicates the interpretation of the endpoints of AEGON (e.g. double-blind study on antibiotic use).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort 1: VRE negative at admission
150 patients meeting the following inclusion criteria:
Exclusion criteria:
|
Microbial analyses will be performed from the rectal swabs obtained.
|
Cohort 2: VRE positive at admission
A total 20 known VREf-positive patients meeting the following inclusion criteria:
|
Microbial analyses will be performed from the rectal swabs obtained.
Only performed for cohort 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VREf - Intestinal microbiota
Time Frame: Baseline
|
Primary Outcome for Cohort 1: Rate of VREf intestinal colonization detected by enrichment culture or specific PCR at time of uptake not detected by standard culture methods
|
Baseline
|
VREf - Patient rooms
Time Frame: Change from baseline spread to spread at 10 weeks.
|
Primary Outcome for Cohort 2: Description of the spread of VREf in single rooms newly enrolled in known VREf-positive patients
|
Change from baseline spread to spread at 10 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Standard culture VREf detection
Time Frame: baseline and every week up to 10 weeks max.
|
Cohort 1: Quantitative detection limit of standard culture methods for VREf detection compared to enrichment culture and qPCR (quantitative polymerase chain reaction)
|
baseline and every week up to 10 weeks max.
|
Antibiotics
Time Frame: baseline and every week up to 10 weeks max.
|
Cohort 1: Identification of antibiotic classes that increase the risk of clonal expansion and subsequent domination by VREf.
Domination by VREf is defined as the combination of cultural VREf detection from a sample and 16S rRNA (16S ribosomal ribonucleic acid) sequencing of the relative frequency of the Enterococcus genus over 30% as the most abundant genus in the sample.
|
baseline and every week up to 10 weeks max.
|
Inadequately administered antibiotics
Time Frame: baseline and every week up to 10 weeks max.
|
Cohort 1: Proportion of inadequately administered antibiotics, defined as unnecessary, too long, too broad or too high doses in patients who develop VREf domination (see definition above) compared to patients without VREf acquisition and patients with VREf acquisition but without domination.
|
baseline and every week up to 10 weeks max.
|
Adequate antibiotic
Time Frame: baseline and every week up to 10 weeks max.
|
Cohort 1: Rate of patients with no or adequate antibiotic therapy compared to patients with inadequate antibiotic therapy who develop a new colonization with VREf during the stay
|
baseline and every week up to 10 weeks max.
|
Influence of antibiotic exposure duration
Time Frame: baseline and every week up to 10 weeks max.
|
Cohort 1: Influence of antibiotic exposure duration on microbiota
|
baseline and every week up to 10 weeks max.
|
Influence of antibiotic class
Time Frame: baseline and every week up to 10 weeks max.
|
Cohort 1: Influence of antibiotic class on microbiota
|
baseline and every week up to 10 weeks max.
|
VREf contamination
Time Frame: baseline at least every 72 hours up to max of 20 days.
|
Cohort 2: Identification of high risk objects and surfaces for VREf contamination in patient rooms with known VREf-positive patients
|
baseline at least every 72 hours up to max of 20 days.
|
Correlation of the antibiotic exposure
Time Frame: baseline at least every 72 hours up to max of 20 days.
|
Cohort 2: Correlation of the antibiotic exposure of already known VREf-positive patients with the contamination load of objects and surfaces in the corresponding patient room.
|
baseline at least every 72 hours up to max of 20 days.
|
Contamination load of objects
Time Frame: baseline at least every 72 hours up to max of 20 days.
|
Cohort 2: Correlation of the relative proportion of enterococci in intestinal microbiota with the contamination load of objects and surfaces in the associated patient room
|
baseline at least every 72 hours up to max of 20 days.
|
Cleaning quality
Time Frame: baseline at least every 72 hours up to max of 20 days.
|
Cohort 2: Correlation of cleaning quality with the contamination load of VREf on objects and surfaces in rooms of known VRE-positive patients
|
baseline at least every 72 hours up to max of 20 days.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jörg Janne Vehreschild, Prof. Dr. med, University Hospital of Cologne
- Principal Investigator: Maria J.G.T. Vehreschild, Prof. Dr. med, University Hospital of Cologne
Publications and helpful links
General Publications
- Gastmeier P, Schroder C, Behnke M, Meyer E, Geffers C. Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother. 2014 Jun;69(6):1660-4. doi: 10.1093/jac/dku035. Epub 2014 Mar 9.
- Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fatkenheuer G, Wisplinghoff H, Seifert H, Vehreschild MJ. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012 Dec;40(6):613-9. doi: 10.1007/s15010-012-0269-y. Epub 2012 Jun 5.
- Vehreschild MJGT, Haverkamp M, Biehl LM, Lemmen S, Fatkenheuer G. Vancomycin-resistant enterococci (VRE): a reason to isolate? Infection. 2019 Feb;47(1):7-11. doi: 10.1007/s15010-018-1202-9. Epub 2018 Sep 3.
- Biehl LM, Higgins P, Wille T, Peter K, Hamprecht A, Peter S, Dorfel D, Vogel W, Hafner H, Lemmen S, Panse J, Rohde H, Klupp EM, Schafhausen P, Imirzalioglu C, Falgenhauer L, Salmanton-Garcia J, Stecher M, Vehreschild JJ, Seifert H, Vehreschild MJGT. Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort study in haematological and oncological wards. Clin Microbiol Infect. 2019 Aug;25(8):1013-1020. doi: 10.1016/j.cmi.2018.12.029. Epub 2019 Jan 12.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-1325
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibiotic Resistant Infection
-
University of Novi SadActive, not recruitingPostoperative Complications | Infection, Bacterial | Antibiotic Side Effect | Antibiotic Resistant Infection | Antibiotic Resistant Strain | Antibiotic Reaction | Infection, LaboratorySerbia
-
British University In EgyptCompleted
-
Cairo UniversityNot yet recruitingAntibiotic Side Effect | Antibiotic Resistant Infection
-
Sung-Han KimUnknownAntibiotic Resistant InfectionKorea, Republic of
-
Lund UniversityCompleted
-
Fundación Pública Andaluza para la gestión de la...CompletedAntibiotic Resistant InfectionSpain
-
Hospital Universitario Mayor MederiUniversidad del RosarioNot yet recruitingAntibiotic Resistant Strain | Biliary Infection
-
St. Jude Children's Research HospitalJohns Hopkins University; Tarleton State UniversityCompletedAntibiotic Resistant InfectionUnited States, Guatemala, El Salvador, Panama
-
Mahidol UniversityCompletedAntibiotic Resistant InfectionThailand
Clinical Trials on Rectal swabs - microbiological analysis
-
University Medical Center GoettingenDepartment of Medicine II, University Hospital Rostock; Medical Department... and other collaboratorsCompleted
-
Erasmus Medical CenterRecruitingPregnancy Complications | Gut Microbiota | Obesity, MaternalNetherlands
-
Rennes University HospitalCompleted
-
University Medical Center GoettingenRecruitingPancreatic CancerGermany
-
Charite University, Berlin, GermanyPro-Implant Foundation; Ceram Tec GmbHUnknownTotal Hip Replacement | Biofilm | SonicationGermany
-
University of BolognaCompletedType 2 Diabetes Mellitus | Chronic PeriodontitisItaly
-
Oncology Institute of Southern SwitzerlandInstitute of Oncology ResearchRecruitingEpithelial Ovarian CancerSwitzerland
-
Medical University of ViennaUniversity of ViennaUnknown
-
Military Institute of Medicine, PolandCompletedIntensive Care Unit | Bloodstream Infection | Antibiotic Resistant StrainPoland
-
Kepler University HospitalCompleted